The Impact of Carboplatin Dosing Design Using Adjusted Serum Creatinine on Carboplatin Plus Paclitaxel Therapy for Ovarian Cancer
ABSTRACT Background Carboplatin (CBDCA) is a mainstay of chemotherapy for ovarian cancer and its dose is determined in proportion to the estimated creatinine clearance (CCr). Serum creatinine (SCr) values necessary to estimate CCr vary by measurement method: adding 0.2 mg/dL to SCr by enzymatic meth...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70804 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850144439905812480 |
|---|---|
| author | Shu Kato Kaede Baba Kanako Mamishin Mao Uematsu Mai Shimura Akira Hirota Misao Fukuda Nobuyuki Takahashi Takehiro Nakao Hiromichi Nakajima Chikako Funasaka Chihiro Kondoh Kenichi Harano Yoichi Naito Nobuaki Matsubara Ako Hosono Toshikatsu Kawasaki Toru Mukohara |
| author_facet | Shu Kato Kaede Baba Kanako Mamishin Mao Uematsu Mai Shimura Akira Hirota Misao Fukuda Nobuyuki Takahashi Takehiro Nakao Hiromichi Nakajima Chikako Funasaka Chihiro Kondoh Kenichi Harano Yoichi Naito Nobuaki Matsubara Ako Hosono Toshikatsu Kawasaki Toru Mukohara |
| author_sort | Shu Kato |
| collection | DOAJ |
| description | ABSTRACT Background Carboplatin (CBDCA) is a mainstay of chemotherapy for ovarian cancer and its dose is determined in proportion to the estimated creatinine clearance (CCr). Serum creatinine (SCr) values necessary to estimate CCr vary by measurement method: adding 0.2 mg/dL to SCr by enzymatic methods commonly used in Japan equates to SCr calculated using the Jaffe method, which is widely adopted outside Japan. Although adjustment by adding 0.2 mg/dL to SCr by enzymatic methods may avoid the potential overdose of CBDCA, its impact on the dose intensity (DI) of chemotherapy is unclear. Methods We retrospectively studied patients with ovarian cancer treated with CBDCA + paclitaxel (PTX) (TC) after primary surgery. Patients were classified into Cohort A (dose‐dense [dd‐]TC, SCr‐adjusted, n = 18), B (dd‐TC, non‐adjusted, n = 8), C (tri‐weekly [tw‐]TC, SCr‐adjusted, n = 6), and D (tw‐TC, non‐adjusted, n = 15), and DI and DI‐related measures including average relative DI (ARDI, [RDI of CBDCA + RDI of PTX]/2]) known to correlate with patients’ prognoses were compared. Results Although the DI of CBDCA did not differ between Cohorts A and B, the DI of PTX and proportion of patients with ARDI ≥ 85% were higher in Cohort A than B (78 vs. 13%, p = 0.002) as a result of less frequent treatment modification. There was no difference in these measures between Cohorts C and D. Conclusion Adjustment of SCr when calculating the CBDCA dose did not compromise the DI of total CBDCA and may rather contribute to maintaining DI in patients receiving dd‐TC. |
| format | Article |
| id | doaj-art-77ad26e1de6d426bbd447fb8d56161f7 |
| institution | OA Journals |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-77ad26e1de6d426bbd447fb8d56161f72025-08-20T02:28:23ZengWileyCancer Medicine2045-76342025-04-01147n/an/a10.1002/cam4.70804The Impact of Carboplatin Dosing Design Using Adjusted Serum Creatinine on Carboplatin Plus Paclitaxel Therapy for Ovarian CancerShu Kato0Kaede Baba1Kanako Mamishin2Mao Uematsu3Mai Shimura4Akira Hirota5Misao Fukuda6Nobuyuki Takahashi7Takehiro Nakao8Hiromichi Nakajima9Chikako Funasaka10Chihiro Kondoh11Kenichi Harano12Yoichi Naito13Nobuaki Matsubara14Ako Hosono15Toshikatsu Kawasaki16Toru Mukohara17Department of Pharmacy National Cancer Center Hospital East Kashiwa JapanDepartment of Pharmacy National Cancer Center Hospital East Kashiwa JapanDepartment of Pharmacy National Cancer Center Hospital East Kashiwa JapanDepartment of Medical Oncology National Cancer Center Hospital East Kashiwa JapanDepartment of Medical Oncology National Cancer Center Hospital East Kashiwa JapanDepartment of Medical Oncology National Cancer Center Hospital East Kashiwa JapanDepartment of Medical Oncology National Cancer Center Hospital East Kashiwa JapanDepartment of Medical Oncology National Cancer Center Hospital East Kashiwa JapanDepartment of Medical Oncology National Cancer Center Hospital East Kashiwa JapanDepartment of Medical Oncology National Cancer Center Hospital East Kashiwa JapanDepartment of Medical Oncology National Cancer Center Hospital East Kashiwa JapanDepartment of Medical Oncology National Cancer Center Hospital East Kashiwa JapanDepartment of Medical Oncology National Cancer Center Hospital East Kashiwa JapanDepartment of Medical Oncology National Cancer Center Hospital East Kashiwa JapanDepartment of Medical Oncology National Cancer Center Hospital East Kashiwa JapanDepartment of Medical Oncology National Cancer Center Hospital East Kashiwa JapanDepartment of Pharmacy National Cancer Center Hospital East Kashiwa JapanDepartment of Medical Oncology National Cancer Center Hospital East Kashiwa JapanABSTRACT Background Carboplatin (CBDCA) is a mainstay of chemotherapy for ovarian cancer and its dose is determined in proportion to the estimated creatinine clearance (CCr). Serum creatinine (SCr) values necessary to estimate CCr vary by measurement method: adding 0.2 mg/dL to SCr by enzymatic methods commonly used in Japan equates to SCr calculated using the Jaffe method, which is widely adopted outside Japan. Although adjustment by adding 0.2 mg/dL to SCr by enzymatic methods may avoid the potential overdose of CBDCA, its impact on the dose intensity (DI) of chemotherapy is unclear. Methods We retrospectively studied patients with ovarian cancer treated with CBDCA + paclitaxel (PTX) (TC) after primary surgery. Patients were classified into Cohort A (dose‐dense [dd‐]TC, SCr‐adjusted, n = 18), B (dd‐TC, non‐adjusted, n = 8), C (tri‐weekly [tw‐]TC, SCr‐adjusted, n = 6), and D (tw‐TC, non‐adjusted, n = 15), and DI and DI‐related measures including average relative DI (ARDI, [RDI of CBDCA + RDI of PTX]/2]) known to correlate with patients’ prognoses were compared. Results Although the DI of CBDCA did not differ between Cohorts A and B, the DI of PTX and proportion of patients with ARDI ≥ 85% were higher in Cohort A than B (78 vs. 13%, p = 0.002) as a result of less frequent treatment modification. There was no difference in these measures between Cohorts C and D. Conclusion Adjustment of SCr when calculating the CBDCA dose did not compromise the DI of total CBDCA and may rather contribute to maintaining DI in patients receiving dd‐TC.https://doi.org/10.1002/cam4.70804adjuvant chemotherapycarboplatincreatinineovarian cancerpaclitaxel |
| spellingShingle | Shu Kato Kaede Baba Kanako Mamishin Mao Uematsu Mai Shimura Akira Hirota Misao Fukuda Nobuyuki Takahashi Takehiro Nakao Hiromichi Nakajima Chikako Funasaka Chihiro Kondoh Kenichi Harano Yoichi Naito Nobuaki Matsubara Ako Hosono Toshikatsu Kawasaki Toru Mukohara The Impact of Carboplatin Dosing Design Using Adjusted Serum Creatinine on Carboplatin Plus Paclitaxel Therapy for Ovarian Cancer Cancer Medicine adjuvant chemotherapy carboplatin creatinine ovarian cancer paclitaxel |
| title | The Impact of Carboplatin Dosing Design Using Adjusted Serum Creatinine on Carboplatin Plus Paclitaxel Therapy for Ovarian Cancer |
| title_full | The Impact of Carboplatin Dosing Design Using Adjusted Serum Creatinine on Carboplatin Plus Paclitaxel Therapy for Ovarian Cancer |
| title_fullStr | The Impact of Carboplatin Dosing Design Using Adjusted Serum Creatinine on Carboplatin Plus Paclitaxel Therapy for Ovarian Cancer |
| title_full_unstemmed | The Impact of Carboplatin Dosing Design Using Adjusted Serum Creatinine on Carboplatin Plus Paclitaxel Therapy for Ovarian Cancer |
| title_short | The Impact of Carboplatin Dosing Design Using Adjusted Serum Creatinine on Carboplatin Plus Paclitaxel Therapy for Ovarian Cancer |
| title_sort | impact of carboplatin dosing design using adjusted serum creatinine on carboplatin plus paclitaxel therapy for ovarian cancer |
| topic | adjuvant chemotherapy carboplatin creatinine ovarian cancer paclitaxel |
| url | https://doi.org/10.1002/cam4.70804 |
| work_keys_str_mv | AT shukato theimpactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT kaedebaba theimpactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT kanakomamishin theimpactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT maouematsu theimpactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT maishimura theimpactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT akirahirota theimpactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT misaofukuda theimpactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT nobuyukitakahashi theimpactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT takehironakao theimpactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT hiromichinakajima theimpactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT chikakofunasaka theimpactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT chihirokondoh theimpactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT kenichiharano theimpactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT yoichinaito theimpactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT nobuakimatsubara theimpactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT akohosono theimpactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT toshikatsukawasaki theimpactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT torumukohara theimpactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT shukato impactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT kaedebaba impactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT kanakomamishin impactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT maouematsu impactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT maishimura impactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT akirahirota impactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT misaofukuda impactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT nobuyukitakahashi impactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT takehironakao impactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT hiromichinakajima impactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT chikakofunasaka impactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT chihirokondoh impactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT kenichiharano impactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT yoichinaito impactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT nobuakimatsubara impactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT akohosono impactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT toshikatsukawasaki impactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer AT torumukohara impactofcarboplatindosingdesignusingadjustedserumcreatinineoncarboplatinpluspaclitaxeltherapyforovariancancer |